Download MendeleyPan-H7 influenza human antibody virus neutralization depends on avidity and steric hindrance.
Gilchuk, I.M., Dong, J., Irving, R.P., Buchman, C.D., Armstrong, E., Turner, H.L., Li, S., Ward, A.B., Carnahan, R.H., Crowe Jr., J.E.(2025) JCI Insight 10
- PubMed: 40471690
- DOI: https://doi.org/10.1172/jci.insight.186182
- Primary Citation of Related Structures:
9BT5 - PubMed Abstract:
H7N9 avian influenza virus is a zoonotic influenza virus of public health concern, with a 39% mortality rate in humans. H7N9-specific prevention or treatments for humans have not been approved. We previously isolated a human monoclonal antibody (mAb) designated H7-235 that broadly reacts to diverse H7 viruses and neutralizes H7N9 viruses in vitro. Here, we report the crystal structure of H7 HA1 bound to the fragment antigen-binding region (Fab) of recombinant H7-235 (rH7-235). The crystal structure revealed that rH7-235 recognizes residues near but outside of the receptor binding site (RBS). Nevertheless, the rH7-235 IgG potently inhibits hemagglutination mediated by H7N9 viruses due to avidity effect and Fc steric hindrance. This mAb prophylactically protects mice against weight loss and death caused by challenge with lethal H7N9 viruses in vivo. rH7-235 mAb neutralizing activity alone is sufficient for protection when used at high dosed in a prophylactic setting. This study provides insights into mechanisms of viral neutralization by protective broadly reactive anti-H7 antibodies informing the rational design of therapeutics and vaccines against H7N9 influenza virus.
- The Vanderbilt Center for Antibody Therapeutics, Vanderbilt University Medical Center, Nashville, United States of America.
Organizational Affiliation:
